Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.47 |
| ▸ | NQO2 | P16083 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.43 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12106973 | 0.89 | MET (0.60) | METNQO2GPR119SLC2A1 | |
| SCHEMBL12870216 | 0.89 | MET (0.61) | METNQO2GPR119SLC2A1CHEK2 | |
| SCHEMBL12857962 | 0.88 | MET (0.59) | METNQO2 | |
| SCHEMBL12858279 | 0.87 | MET (0.47) | METNQO2GPR119SLC2A1CHEK2 | |
| SCHEMBL2531744 | 0.79 | MET (0.62) | METNQO2GPR119SLC2A1CHEK2 | |
| SCHEMBL1151066 | 0.78 | MET (0.62) | METNQO2 | |
| SCHEMBL3084089 | 0.78 | MET (0.78) | METNQO2GPR119 | |
| SCHEMBL12858128 | 0.77 | MET (0.39) | METHDAC1 | |
| SCHEMBL12106976 | 0.77 | MET (0.76) | METNQO2 | |
| SCHEMBL12760969 | 0.76 | MET (0.78) | METNQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034474-A1 | PYRIDAZINONE DERIVATIVES | MET, ERBB2, BRAF | MET 1/4885NQO2 588/4885GPR119 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.